Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Horikoshi

Showing results (41-50 of 135) with videos related to

Pageof 14
Sort By:
Antimicrobial Agents and Chemotherapy|October 1, 1973
Ticarcillin therapy of infectionsV Rodriguez, G P Bodey, N Horikoshi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 1991
Direct interaction between adenovirus E1A protein and the TATA box binding transcription factor IIDN Horikoshi, K Maguire, A Kralli, et al.
Journal of Virology|March 1, 1995
Adenovirus E1A proteins interact with the cellular YY1 transcription factorB A Lewis, G Tullis, E Seto, et al.
Molecular and Cellular Biology|January 1, 1995
Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repressionN Horikoshi, A Usheva, J Chen, et al.
Oncogene|August 1, 1991
Interactions between adenovirus E1A and members of the AP-1 family of cellular transcription factorsK Maguire, X P Shi, N Horikoshi, et al.
British Journal of Cancer|January 1, 1996
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerI Adachi, T Watanabe, S Takashima, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 1, 1985
[Case report of meningeal carcinomatosis of gastric cancer successfully treated with intrathecal and systemic chemotherapy]N Usui, M Ogawa, J Inagaki, et al.
Oncology|November 5, 1999
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study GroupK Sugimachi, Y Maehara, N Horikoshi, et al.
British Journal of Cancer|July 20, 2000
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupA Ohtsu, H Baba, Y Sakata, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-upY Ito, T Mukaiyama, M Ogawa, et al.
Pageof 14

Showing results (41-50 of 135) with videos related to

Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|October 1, 1973
Ticarcillin therapy of infectionsV Rodriguez, G P Bodey, N Horikoshi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 1991
Direct interaction between adenovirus E1A protein and the TATA box binding transcription factor IIDN Horikoshi, K Maguire, A Kralli, et al.
Journal of Virology|March 1, 1995
Adenovirus E1A proteins interact with the cellular YY1 transcription factorB A Lewis, G Tullis, E Seto, et al.
Molecular and Cellular Biology|January 1, 1995
Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repressionN Horikoshi, A Usheva, J Chen, et al.
Oncogene|August 1, 1991
Interactions between adenovirus E1A and members of the AP-1 family of cellular transcription factorsK Maguire, X P Shi, N Horikoshi, et al.
British Journal of Cancer|January 1, 1996
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerI Adachi, T Watanabe, S Takashima, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 1, 1985
[Case report of meningeal carcinomatosis of gastric cancer successfully treated with intrathecal and systemic chemotherapy]N Usui, M Ogawa, J Inagaki, et al.
Oncology|November 5, 1999
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study GroupK Sugimachi, Y Maehara, N Horikoshi, et al.
British Journal of Cancer|July 20, 2000
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupA Ohtsu, H Baba, Y Sakata, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-upY Ito, T Mukaiyama, M Ogawa, et al.
Pageof 14